President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer(5) · Spero Therapeutics, Inc. (SPRO)

Esther Rajavelu

A named executive officer of Spero Therapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,061,496

Salary $577,179Stock awards $413,705Bonus $687,479

FY2024: $856,479

1st of 3 named executive officers at Spero Therapeutics by FY2025 total.

3 named officers on file for Spero Therapeutics, FY2025

Esther Rajavelu’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Spero Therapeutics’s whole pay program stands against its peers

  • Spero Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SPRO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Esther Rajavelu’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Esther Rajavelu compensation by year

Spero Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Spero Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$483,313$577,179
Bonus$0$687,479
Stock awards$188,190$413,705
Option awards$0$0
Non-equity incentive$173,993$372,000
Pension and deferred compensation$0$0
All other$10,984$11,134
Total$856,479$2,061,496

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Spero Therapeutics, Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-182201, and prior-year filings.

How this page was built: the Spero Therapeutics, Inc. filed document, accession 0001193125-26-182201. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.

$856K
$2.1M
FY24
FY25
SalaryBonusNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU366,139$853,104—
RSU185,000$431,050—
RSU150,000$349,500—
RSU89,899$209,465—

Per the Outstanding Equity Awards at Fiscal Year-End table in Spero Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2025 proxy (filed April 27, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-09Sale—40,851$1.04946,000
2026-05-04Sale—25,240$2.51986,851

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Spero Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Esther Rajavelu · this pagePresident and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer(5)$2,061,496
Satyavrat ShuklaFormer President and Chief Executive Officer(6)$2,025,178
Tim KeutzerChief Operating Officer$1,440,820

Board service

Spero Therapeutics board · FY2025

How this board is paid

Company policy: Spero Therapeutics pays directors a $40,000 cash retainer and $20,000 in RSUs. As stated in Spero Therapeutics's FY2025 proxy.

The full Spero Therapeutics compensation record

free company brief

This page is one person within Spero Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Spero Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Esther Rajavelu's compensation dossier · One-time report. No refunds.